603987.SH
Shanghai Kindly Enterprises Development Group Co., Ltd.
SSE · Healthcare · Medical - Instruments & Supplies · CN
CNY 7.11
−0.28%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.3B | 2.3B | 2.3B | 2.5B | 3.1B |
| Cost of Revenue | 1.5B | 1.5B | 1.5B | 1.7B | 2.1B |
| Gross Profit | 753.5M | 759.9M | 735.6M | 796.9M | 1.1B |
| Operating Expenses | |||||
| R&D Expense | 86.0M | 90.5M | 106.2M | 100.6M | 123.0M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 178.8M | 178.6M | 176.8M | 164.1M | 211.2M |
| Selling & Marketing Expense | 188.8M | 187.0M | 194.3M | 227.3M | 309.4M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 501.2M | 498.8M | 513.0M | 541.5M | 685.6M |
| Cost and Expenses | 2.0B | 2.0B | 2.0B | 2.2B | 2.8B |
| Operating Income (EBIT) | 305.4M | 310.7M | 255.1M | 301.0M | 399.5M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 302.1M | 307.6M | 252.2M | 300.5M | 399.4M |
| Income Tax Expense | 46.2M | 46.5M | 18.4M | 24.1M | 25.2M |
| Bottom Line | |||||
| Net Income | 233.7M | 240.3M | 215.3M | 230.9M | 311.7M |
| Earnings from Cont. Ops | 256.0M | 261.1M | 233.8M | 276.4M | 374.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 233.7M | 240.3M | 215.3M | 230.9M | 311.7M |
| Per Share | |||||
| Basic EPS | CN¥0.53 | CN¥0.55 | CN¥0.49 | CN¥0.53 | CN¥0.71 |
| Diluted EPS | CN¥0.53 | CN¥0.55 | CN¥0.49 | CN¥0.53 | CN¥0.71 |
| Revenue Per Share | CN¥5.08 | CN¥5.26 | CN¥5.15 | CN¥5.63 | CN¥7.10 |
| Shares | |||||
| Basic Shares Outstanding | 450.6M | 437.0M | 439.4M | 435.7M | 439.1M |
| Diluted Shares Outstanding | 450.6M | 437.0M | 439.4M | 435.7M | 439.1M |
| Profitability Metrics | |||||
| EBITDA | — | 460.9M | 409.9M | 449.6M | 541.2M |
| D&A | — | 150.2M | 154.8M | 148.6M | 141.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026